To support mRNA research and therapeutic applications, Azenta offers custom mRNA synthesis and circular RNA with industry-leading project completion time, a wide range of deliverables, and best-in-class quality.
Synthetic mRNA comes from a template nucleotide sequence of DNA. The process starts with codon optimization of this sequence for optimal transcription. The gene is synthesized, cloned into a vector, and verified by Sanger sequencing. The plasmid DNA is then amplified, target mRNA sequence linearized, and used as a template for in vitro transcription.
The circularization of coding RNAs into circRNAs has generated considerable interest as an approach to extend the duration of protein translation, thanks to their covalently closed structures and increased stability inside the cells. In the context of RNA-based therapeutics development, this has the potential to unveil better targets or gene delivery vectors with high pharmaceutical stability and biostability relative to current standard-of-care linear mRNA. Azenta has developed a proprietary and first-in-market workflow to produce high-quality circular RNA. Based on a group I intron self-splicing system, our process leads to improved circularization efficiency for high-yield circRNA products with favorable characteristics for therapeutic development.
mRNA products are provided as a dry powder, fully lyophilized and shipped at room temperature. Below is a summary of what to expect from your custom mRNA synthesis order.
|mRNA Synthetic Motifs||Purified Synthetic Yield||Synthetic Length||Estimated Completion Time||Quality Control|
|ncRNA: Non-coding RNA||40 ug – 2000 ug||< 2000 bp||In as few as 2 weeks||- 100% sequence accuracy from Sanger sequencing of template
- Certificate of analysis (CoA)
- Gel electrophoresis size visualization
- Agilent 2100 Bioanalyzer verification (optional)2
|Cap0 mRNA: m7Gppp-capped mRNA with polyA tail||2001-4000 bp||In as few as 4 weeks|
|Cap1 mRNA: m7GpppNm-capped mRNA with polyA tail||4001-6000 bp||In as few as 5 weeks|
|Pseudouridine modification (optional)1||> 6001 bp||Custom|
Need mRNA fast for your pilot study? Below is a summary of what to expect from your off-the-shelf GFP mRNA order.
|coGFP3 control RNAs||Scale||Estimated Completion Time|
|Linear with 5’ cap 1 and a ~100A tail||100 ug||As fast as 1 week|
|Circular RNA||20 ug||In as few as 2 weeks|
1. Pseudouridine is a common RNA modification to replace uridine in IVT mRNA. It has been demonstrated to enhance RNA stability and decrease anti-RNA immune response.
2. Agilent 2100 Bioanalyzer utilizes LabChip technology to automate the measurement of both the concentration and the integrity/purity of mRNA samples.
3. Green fluorescent protein (GFP) 2 from Pontellina plumata, also known as ppluGFP2 (Shagin et al., 2004).
If you have custom requests or require any pre-project consultation, please contact our expert project management team.
Poly(A) tail sequences can impact the integrity of your mRNA plasmids for in vitro transcription. While longer poly(A) tails have been shown to increase their stability, tails greater than 100 bases are susceptible to truncations. Learn how the proprietary mRNA plasmid preparation protocol from Azenta can help you generate higher yields and preserve poly(A) tails of greater lengths compared to standard protocols for high-fidelity templates in our tech note.
In vitro transcription (IVT) is a powerful technique to generate messenger RNA (mRNA) for a wide array of research and therapeutic applications. Transfection of mRNA enables very high protein expression, comparable to viral systems, with rapid onset. Read our tech note to learn how IVT, coupled with gene synthesis, can be used to synthesize mRNA of virtually any sequence quickly and efficiently.
Lentiviral vectors have proven effective at delivery of genetic material or gene editing technology for ex vivo processing, but the benefits and promise of Adeno-associated virus (AAV) and mRNA tools for in vivo immunotherapy have garnered recent interest. In this poster, we present streamlined approaches for lentiviral, AAV, and mRNA production that improves data quality through innovative synthesis and sequencing methodologies as compared to current standards